Global Infectious Disease Control hampered by the CBD Nagoya Protocol So far, none of the models used by international networks of biobanks to arrange the legal responsibility under the CBD-Nagoya protocol works efficiently.
Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination Influenza vaccination reduces the number of influenza virus infections but not the overall number of illness.
Risk of measles outbreaks increases with decreasing vaccination coverage Vaccination coverage for vaccinations in the Dutch National Vaccination Program (NIP) decreased slightly by about half a percent for the third consecutive year.
EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.
Moderate flu season Last winter season, the duration and severity of the influenza epidemic was moderate compared to previous years.
Step forward in the battle against pertussis Addition of an extra adjuvant (additive) to the current pertussis vaccines could enhance the effectivity of these vaccines.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
Measles epidemic and Salmonella outbreak cost nearly six million euros The most recent measles epidemic and outbreak of Salmonella Thomson due to smoked salmon have cost 3.9 and 1.7 million euros, respectively.
Flu season in the winter of 2014 / 2015 more severe and longer than preceding years The flu epidemic in the winter of 2014 / 2015 lasted 21 weeks and as such was the longest epidemic ever recorded in the Netherlands. Nearly two million people suffered from flu-like symptoms.
RIVM participates in large EU project to head up global fight against infectious diseases COMPARE, a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology.